NAGE at a glance
Niagen Bioscience, Inc. (NAGE, SEC CIK 1386570) filed its latest 10-K annual report on March 4, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as July 8, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Niagen Bioscience, Inc. (NAGE) reported revenue of $129.4 million (up 29.9% from FY2024) and net income of $17.4 million. Diluted EPS was $0.20.
- As of September 30, 2026, 22 institutional investment managers tracked by SignalX reported holding Niagen Bioscience, Inc. (NAGE) shares worth $39.6 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $129.4M
- +29.9% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 22 funds
- $39.6M · −2 vs prior quarter
- Latest 8-K
- Nov 4, 2026
- Item 2.02 · Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Competitive risk: FDA’s September 2025 NMN decision increased lower-priced competition, with ingredient-business financial impacts already experienced
- Legal risk: Elysium fee award of approximately $9.2 million reversed October 30, 2026, but further review remains possible
- Regulatory risk: Putative consumer class actions challenge Tru Niagen® advertising and marketing claims
- Operational risk: Marketplace suspension of a Tru Niagen® listing during Q2 2026 caused lost revenue
- Liquidity risk: $69.5 million cash and no line-of-credit borrowings outstanding, with additional financing potentially required beyond twelve months
Management Discussion & Analysis
- Q3 revenue $27.2M, down 20% YoY from $34.0M, driven by Consumer Products and Ingredients declines
- Ingredients worst segment: sales $3.8M, down 47%; Consumer Products best: sales $23.3M, down 10%
- Gross margin 62.9% vs 64.5% YoY, with Ingredients margin 51.3% vs 59.1%
- Cash $69.5M at September 30; operating cash flow $4.2M vs $12.8M YoY
- $5.1M investing inflow from divestiture; $4.6M financing outflow including $5.1M share repurchases
- Near-term headwinds: softer downstream demand, variable partner orders, competitive pricing, and elevated marketing investment
AI summary of the NAGE 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 fiscal 2026 earnings announcement for quarter ended September 30, 2026
- Exhibit 99.1 contains Niagen Bioscience’s detailed financial results and management commentary
Item 7.01: Regulation FD Disclosure
- Corporate presentation released November 4, 2026, providing updated company information to investors
- Exhibit 99.2 contains the presentation, including potentially material business and strategic updates
Item EX-99.1: Item EX-99.1
- Q3 net sales $27.2M, down from $34.0M; Tru Niagen contributed $23.3M
- Gross margin 62.9%, while net loss reached $1.2M versus $4.6M net income last year
Item EX-99.2: Item EX-99.2
- Q3 2026 earnings presentation: net sales $27.2M, down 20% year over year, with Tru Niagen sales $23.3M
- Profitability weakened: gross margin 62.9% versus 64.5%, net loss $(1.2)M, and Adjusted EBITDA $0.5M versus $6.4M
Item EX-99.1: Item EX-99.1
- Q2 sales $29.8M, down from $31.1M; Tru Niagen contributed $24.2M while direct-to-consumer sales grew 23% year-over-year
- Gross margin 64.8%; operating income fell to $0.7M from $3.2M as operating expenses increased to $18.6M
Item 2.02: Results of Operations and Financial Condition
- Earnings release covers quarter ended June 30, 2026
- Exhibit 99.1 contains Niagen Bioscience’s reported quarterly financial results
Item 7.01: Regulation FD Disclosure
- Corporate presentation released August 4, 2026, providing updated company information to investors
- Exhibit 99.2 contains the presentation, including any strategic, operational, or financial updates disclosed by Niagen Bioscience
Item EX-99.2: Item EX-99.2
- Q2 net sales $29.8M, down from $31.1M, while Tru Niagen sales rose to $24.2M from $22.7M
- Gross margin 64.8%, net income $1.0M, diluted EPS $0.01, and Adjusted EBITDA $3.0M
Item 5.07: Submission of Matters to a Vote of Security Holders
- All eight director nominees elected for terms through the 2027 annual meeting
- Steven Rubin and Hamed Shahbazi received notably higher withheld votes, signaling greater shareholder dissent
AI summaries of NAGE 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for NAGE
Don't miss the next NAGE filing
- Alerts as it files. A push when NAGE files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut NAGE, by share count.
- Ask anything. An AI agent that reads every NAGE filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Fried Robert N | A | Jun 30, 2026 | 1,106 | $2.71 |
| Lopez Carlos Luis | A | Jun 30, 2026 | 2,314 | $2.71 |
| Pamir Ozan | A | Jun 30, 2026 | 4,255 | $2.71 |
| YU Wing Tak Wendy | A | Jun 24, 2026 | 31,746 | - |
| Patrick Kristin | A | Jun 24, 2026 | 31,746 | - |
| Shahbazi Hamed | A | Jun 24, 2026 | 31,746 | - |
| Rubin Steven D | A | Jun 24, 2026 | 31,746 | - |
| Ng Wang Yu Gary | A | Jun 24, 2026 | 31,746 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $99.6M | $129.4M |
| Gross Profit | $50.8M | $61.6M | $83.2M |
| Operating Income | - | $7.7M | $16.3M |
| Net Income | -$4.9M | $8.6M | $17.4M |
| Gross Margin | - | 61.8% | 64.3% |
| Op. Margin | - | 7.8% | 12.6% |
| Net Margin | - | 8.6% | 13.4% |
| Balance Sheet | |||
| Total Assets | - | $68.3M | $106.4M |
| Equity | $28.5M | $46.1M | $76.5M |
| ROE | -17.4% | 18.5% | 22.7% |
| Per Share | |||
| EPS | $-0.07 | $0.11 | $0.20 |
| Cash Flow | |||
| Operating CF | - | $12.1M | $13.5M |
Source: XBRL data in Niagen Bioscience, Inc. (NAGE)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate NAGE share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 22 | $39.6M |
| Q2 2026 | 24 | $47.4M |
| Q1 2026 | 27 | $73.0M |
| Q4 2025 | 27 | $106.2M |
| Q3 2025 | 27 | $152.4M |
| Q2 2025 | 27 | $218.5M |
| Q1 2025 | 24 | $69.3M |
| Q4 2024 | 20 | $41.9M |
- Goldman Sachs Group+211.9K (+17%)
- JPMorgan Chase & Co+134.2K (+40%)
- Morgan Stanley+123.1K (+24%)
- Bank of America Corp+48.1K (+16%)
- Vanguard Capital Management LLC+28.8K (+1%)
- Citadel Advisors LLC−412.2K (-65%)
- Renaissance Technologies LLC−372.5K (-56%)
- AQR Capital Management−364.2K (-77%)
- Dimensional Fund Advisors−334.9K (-55%)
- BlackRock−105.0K (-3%)
- Two Sigma Investments+170.1K
- Millennium Management−275.4K
- Principal Financial Group−83.2K
- FMR LLC (Fidelity)−31.8K
Source: 13F-HR filings on SEC EDGAR (aggregated from 198 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
NAGE filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 4, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 10-Q | Aug 4, 2026 | Jun 30, 2026 | Analysis | |
| SC 13G | Jul 29, 2026 | - | - | |
| 4 | Jul 8, 2026 | - | - | - |
| 4 | Jul 8, 2026 | - | - | - |
| 4 | Jul 8, 2026 | - | - | - |
| 8-K | Jun 29, 2026 | - | Analysis | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 8-K | May 6, 2026 | - | Analysis | |
| 10-Q | May 6, 2026 | Mar 31, 2026 | Analysis | |
| 4 | Apr 27, 2026 | - | - | - |
| 8-K | Mar 19, 2026 | - | Analysis | - |
| 8-K | Mar 4, 2026 | - | Analysis | - |
| 10-K | Mar 4, 2026 | Dec 31, 2025 | - | |
| 8-K | Feb 26, 2026 | - | Analysis | - |
| 4 | Feb 24, 2026 | - | - | - |
| 8-K | Dec 22, 2025 | - | - |
Related Health Care companies
- BTMD · biote Corp.Medicinal Chemicals & Botanical Products
- DFTX · Definium Therapeutics, Inc.Medicinal Chemicals & Botanical Products
- FTLF · FITLIFE BRANDS, INC.Medicinal Chemicals & Botanical Products
- MDWD · MediWound Ltd.Medicinal Chemicals & Botanical Products
- USNA · USANA HEALTH SCIENCES INCMedicinal Chemicals & Botanical Products
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
NAGE SEC filings: frequently asked questions
Which institutions hold NAGE stock?
As of September 30, 2026, the largest Niagen Bioscience, Inc. (NAGE) holders among the 13F filers tracked by SignalX were BlackRock ($11.9 million), Vanguard Capital Management LLC ($6.4 million), Goldman Sachs Group ($4.3 million), Vanguard Portfolio Management LLC ($3.4 million), State Street Corp ($3.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was NAGE's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Niagen Bioscience, Inc. (NAGE) reported revenue of $129.4 million (up 29.9% from FY2024) and net income of $17.4 million. Diluted EPS was $0.20. The figures come from the XBRL data in the 10-K.
What did NAGE report in its latest 8-K?
Niagen Bioscience, Inc. (NAGE) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). Q3 fiscal 2026 earnings announcement for quarter ended September 30, 2026.
What are the latest NAGE SEC filings?
Niagen Bioscience, Inc. (NAGE) filed its latest 10-K annual report on March 4, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on July 8, 2026.
What is NAGE's SEC CIK number?
Niagen Bioscience, Inc. (NAGE)'s SEC Central Index Key (CIK) is 1386570. EDGAR lists every NAGE filing under that number.
Ask anything about NAGE
The research agent reads NAGE's filings, financials, insider trades and 13F holders, then answers with sources.